Studies in animals indicate that the half -life (~) of SMC is longer (2-4 hr s) than that of other polypeptide hormones. This is believed to be due to the fact that SHe circulates as part of a binding protein complex. Studies of the t~of SHC in humans have not been possible due to the scarcity of purified SHC. We have estimated the t~of SHC in 11 children (8M, 3F) with GH deficiency. After 2 baseline serum samples were obtained, each child received 5 doses of NPA hGH (0 .1 u/kg/dose) at 12 hr intervals. Serum samples were obtained at 24 hrs and 48 hrs of treatment and at 6 hr intervals after the last dose of hGH. Total SHC was determined on acid-ethanol extracted samples using an RIA specific for SHe. The t~for SMC disappearance was 18.7 ± 2.6 hrs (x ± SEM). T~was not correlated with age, bone age or peak SHC. However, the time elapsed from the last hGH injection to SHC •~peak SHC was correlated with bone age (r· 0.67, p 0.05) . In 8 children, growth velocities on hGH are available (8.2 ± 2.5 cm/yr). Growth velocity was not significantly correlated with bone age, peak SHe or t~. Conclusion: The t~of SHC in GH deficient children is considerably longer than the t~observed in small animals. The prolonged t~of SHC may partially explain the success of present GH treatment regimens in promoting skeletal growth.
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The purpose of this study was to compare the bioactivity (SM) and the bindi ng activity (ILA) of somatomedin in 11 children with growth retardation and persistent GH secretion after cranial irradiation for medulloblastoma or head and neck tumors. Children aged 6-12 yr. first seen 16-54 me after irradiation were investigated over periods of 6-36 mo. Each patient at invervals of 3 me or morũ nderwent 2 to 4 arginine-insulin tests with determinations of GU, SM by the porcine cartilage bioassay and ILA by RRA after plasma acid gel filtration. GH peak values were distributed from severe (5 ng/ml n -5 ). to partial (5-10 ng/ml n -13) or normal range (10 ng/ml n -7 I. All SH values were low «0.5 U/ml) . Mean ILA was lower than control but significantly higher than values obtained in idiopathic hypopituitarism (IU) U/ml Irradiated (n -18) IB (n -5) SM 0 .38 ± 0.04 0 .27 ± 0 .05 NS ILA RRA 0 .67 ± 0.09 0.31 ± 0 .06 p< 0.02 In conclusion, in children with growth retardation after cranial irradiation impaired GH secretion was associated with SM in the hypopituitary range while ILA was only slightly decreased. This is another clinical example of the difficulty in evaluating somatomedin activities in growth retardation. To obtain evidence of autoimmunit y in children with idiopathic hypop1tu1tarism, lymphocyte reactivity to p1tu1tary extract in 9 normal subjects and 3 children with idiopathic hypopitu1tarism was determined. Lymphocyte reactivity to thyroid extract was also studied. Standard lymphoblastic transformation testing by thymidine incorporation was performed with crude human pituitary extract at concentrations of 2.6 or 5.0~g protein/ml & 26 or 50~g/ml. For each set of replicate wells, the arithmetic mean of the square root counts per minute (~ICPH) was calculated. Thymidine incorporation was recorded as the difference of the test counts from the control (~~.~~to 2.5/5.0~g/ml in 9 normal subjects was -6 .0(SO+ 6 .9). The~~to 26/50~g/ml extract was 0.66(S0+8.2). One child had~~34 to the higher extract concentration which was >95% tolerance l~mits of normal subjects, 6 months later the~~·40 to the lower extract concentration (>95% confidence 11mits). This child had no · significant~~to thyr01d extract. He has alopecia dystrophic nails and T and B cell dysfunction .~~to pituitary extract to two other children were within normal 11mits. In conclusion we describe an invitro test to detect cellular hypersensitivity to pituitary extract for patients with hypopituitarism. We report 1 of 3 children tested with persistent lymphocyte reactivity which appears to be organ specific. Clinical and laboratory presentation suggests an autoimmune basis of his disease. Production of human growth hormone by bacteria harboring a plasmid gene i nc r e a s e s the pot en tial availability of the hormone for human clinical use. The eff ica c y of this material has been determined by growth promoting e f f e c t s in rats and cl ini cal chemistry parameters in rats and monke ys. Comparison o f the pharmacokinetics of the hormone admin ist ered intramuscularl y or sub-cutaneously indicates that essentiall y similar effe cts are achieved. Other biochemical properties als o indicate that the s ub-c ut a ne ou s route is not a ssociated with potent ial advers e effects, supporting use of the material f or a variety of c l i n i c a l 1ndicat10ns.
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Stunted growth due to peripheral resistance to somatomedin. a new syndrom. Up to now small stature with high plasma-hGi is known only as Laron-type dwarfism. caused by insufficient response of somatollledin (SM)-production to hGi. Recently we observed a dwarf with constantly elevated levels of hGi and of SM as well. Methods: hGi ace. to Schonberg (1972) . SM ace. to van den Brande &Caju (1974) 
is a 15 mo . old girl of healthy parents who clinically resembles a pituitar.y dwarf. Length 60 em (corresp. to age 3 mo.). weight 5.5 kg (~3 mo.). bone age 11 mo. With 5 mo •• basal hGi was 36.4 ng/ml. after arginine max. 46.6 ng/ml. Blood glucose dropped to 26 mgS under arginine. With 10 mo. basal hGi was 58.2 and 65.5 rtg/ mI. resp •. Basal SM-levels were 1;99 and 2.03 u/ml (normal mean for age 0.41 ulml). Stimulation with hGi caused no further rise.-Biological inactivity of the honnones measured seems iqlrobable. because SM-activity was determined biologically and the high SMlevels presumably are the result of the elevated hGi-secretion. Two other patients who clinically exhibited delayed growth and adolescence showed normal basal hGi-levels but significantly increased spontaneous hGi-secretion by night and. in addition. high plasma-SM. Conclusion. In the first case. a pseudo-hypopituitary dwarf with high plasma-hGi and -SM. absolute peripheral resistance against SM seems to be the most plausible explanation. In the 2 other cases. a certain degree of non-responsiveness to SM mIY playa r6le. 
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Dept. of Pediatrics, Stanford University Medical Center, Stanford, California USA. Synthetic hGH causes both increased somatomedin levels and insulin resistance in humans.
The supply of human pituitary growth hormone (hGH) available has been limited by the number of donors. Recently, methionyl-hGH (Genentech) has been synthesized by recombinant DNA techniques. We have compared synthetic methionyl-hGH with pituitary hGH in twelve normal adult male volunteers. Each patient was given 4 daily doses of 16 U of each hGH with a 10 da y period between hGH preparations. Somatomedin-C (SH-C) by RIA was determined daily. Glucose tolerance tests were done prior to the first and after the fourth injection. The SH-C by RIA increased from a baseline of 1.04 ± 0.07 U/ml to 2.95 + 0.20 U/ml with methionyl-hGH and from 1.11 + 0.06 U/ml to 3.08 + 0.19 U/ml with pituitary hGH. The GTT glucose area increased fro; 348 + 16 mg%-hr to 475 + 30 mg%-hr and the insulin area increased from-I33 + 19 uU/ml-hr to 403 + 55 uU/ml-hr with methionyl-hGH. The glucose area increased fro; 333 ± 14 mg%-hr to 435 ± 25 mg%-hr and the insulin area increased from 110 ± 12 uU/mlhr to 324 + 49 uU/ml-hr with pituitary hGH. The equal somatomedin responses are evidence that the synthetic methionyl hGH has full biological activity. The equal changes in glucose metabolism demonstrate that insulin resistence is linked to monocomponent synthetic hGH as well as pituitary hGH . These studies open the way for explorations of uses of methionyl-hGH in human disease states and developmental disorders.
